Physician profile
Lindsay E Wunder
NPI 1750340204
$2,363.66
in general payments reported to CMS, 2019-2025
25 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.80 · 2023: $104 · 2024: $919 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $397.06 | 2023-2025 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $362.74 | 2023-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $199.54 | 2025 | |
| Pfizer INC. | $181.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $154.93 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $150.28 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $139.65 | 2024-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $113.47 | 2024-2025 | |
| Amgen INC. | $84.17 | 2024-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $77.40 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.65 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.78 | 2025 | Jardiance |
| Dexcom, INC. | $59.35 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $48.82 | 2021-2025 | Shingrix |
| Neurocrine Biosciences, INC. | $47.12 | 2023-2024 | Ingrezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33.18 | 2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $24.04 | 2025 | Spravato |
| Philips North America LLC | $23.05 | 2024 | (5091) Amb Mon & Diag Und |
| Exact Sciences Corporation | $22.25 | 2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $21.65 | 2025 | Aptima |
| Seqirus USA INC | $21.29 | 2024 | Fluad, Flucelvax |
| Biogen, INC. | $20.75 | 2024 | Spinraza |
| Kowa Pharmaceuticals America, INC. | $16.49 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $14.22 | 2024 | Verquvo |
| Medtronic, INC. | $13.89 | 2023 | Vanta Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Wunder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.